Tamoxifen response in breast cancer predicted by protein marker
the ONA take:
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment, according to a study published in Cancer Research.
“Our data indicate that TGFBR2, which detects TGF-beta and thereby activates subsequent cellular responses, could be used as a marker in the clinics to identify patient subgroups that may not benefit from hormone therapy alone and may require additional therapies,” said author Susann Busch, PhD, of Gothenburg University.
Dr. Busch and colleagues analyzed tumor samples of 564 pre-menopausal women who were enrolled in clinical trials from 1986 to 1991 and randomly assigned to either tamoxifen for two years (276) or no systemic treatment (288).
They found that among women who received tamoxifen and had estrogen receptor-positive tumors, those who had low TGFBR2 levels had a 73 percent lower recurrence-free survival rate compared to those with high levels of the protein.
In a follow-up series of laboratory experiments, the same researchers found that, in a drug-resistant cell line, there were low levels of TGFBR2 and abnormal pathway activation.
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|